Abstract: The disclosure provides a method for reducing perfluorocarbon emissions from an aluminum electrolysis, which belongs to the field of aluminum electrolysis. The method includes: placing an aluminum oxide in an electrolytic cell with set parameters for proceeding aluminum electrolysis, and regulating feeding parameters of the aluminum oxide to obtain an electrolyte; adding a set amount of LiF, KF, MgF2 and CaF2 into the electrolyte, and regulating a molar ratio of NaF and AlF3 in the electrolyte to reduce the perfluorocarbon emissions from the aluminum electrolysis.

Abstract: The present disclosure provides a driver circuit, a driving method of the driver circuit, an array substrate and a display device, belonging to the field of display technology. The driver circuit provided by the present disclosure includes a logic control module, a data pin and at least two output pins. The data pin is configured to receive driving data. The logic control module is configured to generate driving control signals in a one-to-one correspondence with the at least two output pins according to the driving data. The driving control signals are configured to control the current flowing through the corresponding output pins.

Abstract: The present disclosure provides modified immune cells or precursors thereof comprising disrupted Fli1. Compositions and methods of treatment are also provided. The disclosure also provides methods for screening T cells, including assessing T cell exhaustion.

Abstract: An antigen binding protein and the use thereof. The antigen binding protein can compete with pembrolizumab for binding to the same or overlapping PD-1 epitope. The antigen binding protein can effectively inhibit the binding of human PD-L1 to human PD-1 with an EC50 of approximately 2 ?g/mL or less.

Abstract: The present disclosure provides compositions and methods for in vitro and in vivo gene editing using a cell penetrating CRISPR-Cas system comprising a cell penetrating Cas and an endosomal escape peptide.

Abstract: The present invention provides a prodrug compound, a preparation method, and the use thereof. In particular, the present invention provides a compound as represented by formula (I), a preparation method, and the use thereof as a prodrug for preparing topical formulations.

Abstract: Methods and compositions for producing fetal hemoglobin and treating a hemoglobinopathy or thalassemia are disclosed. Specifically, the disclosure provides methods of increasing the level of human fetal hemoglobin and/or gamma-globin in a cell or subject, the method comprising administering at least one zinc finger protein 410 (ZNF410) inhibitor to the cell or subject, wherein the subject has a beta-chain hemoglobinopathy, thalassemia, and/or sickle cell disease.

Abstract: Disclosed in the present disclosure is a method for preparing (S)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid and derivatives thereof, comprising: taking a racemate of a compound represented by Formula (I) or a racemate of a salt of the compound represented by Formula (I) as a substrate, and making a R-isomer of the compound represented by Formula (I) in the substrate react under the catalysis of oxidative dehydrogenase to generate imino acid represented by formula (II); and converting the imino acid represented by Formula (II) into an S-isomer of the compound represented by Formula (I) in the presence of pipecolic acid reductase and a coenzyme capable of supplying hydrogen anions. The present disclosure is featured by mild reaction condition, strong stereoselectivity, high reaction efficiency, high conversion rate, etc.

Abstract: Compositions and methods for small molecule control of precise base editing are disclosed.

Abstract: Methods and compositions for producing fetal hemoglobin and treating a hemoglobinopathy or thalassemia are disclosed.

Abstract: The current invention provides methods of combinatorial genetic screening in a cancer cell comprising an enhanced CRISPR-Cas12a system, and compositions comprising the same. Also provided are methods for screening for synergistic combinations of drug targets, as well as the treatment of cancer in a subject in need thereof.

Abstract: Methods and compositions for producing fetal hemoglobin and treating a hemoglobinopathy or thalassemia are disclosed.

Abstract: Methods and compositions for producing fetal hemoglobin and treating a hemoglobinopathy or thalassemia are disclosed.

Abstract: A spacecraft docking system and method thereof are provided. The system comprises an active docking device and a passive docking device. The active docking device comprises an active docking ring and a docking frame. The active docking device further comprises three sets of buffer mechanisms, each set of the buffer mechanisms comprises a main buffer, two screw nut assemblies, and a self-difference buffer. An upper end and a lower end of the screw nut assembly are movably connected to the active docking ring and the docking frame, respectively. The two screw nut assemblies in each set are simultaneously driven and stretched by the main buffer, being also connected to each other through the self-difference buffer, and able to be relatively adjusted and stretched through the self-difference buffer.

Abstract: The invention provides compositions, methods, and kits for the treatment of acute myeloid leukemia in a subject.

Abstract: A spacecraft docking system and method thereof are provided. The system comprises an active docking device and a passive docking device. The active docking device comprises an active docking ring and a docking frame. The active docking device further comprises three sets of buffer mechanisms, each set of the buffer mechanisms comprises a main buffer, two screw nut assemblies, and a self-difference buffer. An upper end and a lower end of the screw nut assembly are movably connected to the active docking ring and the docking frame, respectively. The two screw nut assemblies in each set are simultaneously driven and stretched by the main buffer, being also connected to each other through the self-difference buffer, and able to be relatively adjusted and stretched through the self-difference buffer.

Abstract: Methods and compositions for producing fetal hemoglobin and treating a hemoglobinopathy or thalassemia are disclosed.

Abstract: The invention provides compositions, methods, and kits for the treatment of acute myeloid leukemia in a subject.

Abstract: Provided herein, in some aspects, are methods of determining whether a candidate protein, more specifically a functional domain of a candidate protein, is essential for viability of cells of interest using clustered regularly interspaced short palindromic repeat (CPJSPR)-Cas9 technology which holds great promise for genetic screening and for the discovery of therapeutic targets.

Abstract: The invention provides compositions, methods, and kits for the treatment of acute myeloid leukemia in a subject.